Resource allocation strategies to achieve malaria eradication

Nora Schmit[1]*, Hillary M Topazian[1]*, Matteo Pianella[1]*, Giovanni D Charles[1], Peter Winskill[1], Michael T White[2], Katharina Hauck[3], Azra C Ghani[1]

[1] MRC Centre for Global Infectious Disease Analysis, Imperial College London, London, United Kingdom

[2] Infectious Disease Epidemiology and Analytics G5 Unit, Department of Global Health, Institut Pasteur, Université de Paris, Paris, France

[3] MRC Centre for Global Infectious Disease Analysis, Jameel Institute, Imperial College London, London, United Kingdom

* These authors contributed equally to this work

Corresponding author:

Nora Schmit

MRC Centre for Global Infectious Disease Analysis

Imperial College London

St Mary's Campus

Norfolk Place, London W2 1PG

n.schmit17@imperial.ac.uk

ABSTRACT

Background: Large reductions in the global malaria burden have been achieved in the last

decades, but plateauing funding poses a challenge for progressing towards the ultimate goal of

malaria eradication. We aimed to determine the optimal strategy to allocate global resources to

achieve this goal.

Methods: Using previously published mathematical models of *Plasmodium falciparum* and

Plasmodium vivax transmission incorporating insecticide-treated nets (ITNs) as an illustrative

intervention, we sought to identify the global funding allocation that maximized impact under

defined objectives and across a range of global funding budgets.

Results: We found that the optimal strategy for case reduction closely mirrored an allocation

framework that prioritizes funding for high-transmission settings, resulting in total case

reductions of 76% (optimal strategy) and 66% (prioritizing high-transmission settings) at

intermediate budget levels. Allocation strategies that had the greatest impact on case reductions

were associated with lesser near-term impacts on the global population at risk, highlighting a

trade-off between reducing burden and "shrinking the map" through a focus on near-elimination

settings. The optimal funding distribution prioritized high ITN coverage in high-transmission

settings endemic for *P. falciparum* only, while maintaining lower levels in low-transmission

settings. However, at high budgets, 62% of funding was targeted to low-transmission settings

co-endemic for *P. falciparum* and *P. vivax*.

Conclusions: These results support current global strategies to prioritize funding to high-

burden *P. falciparum*-endemic settings in sub-Saharan Africa to minimize clinical malaria burden

and progress towards elimination but highlight competing goals of reducing the global

population at risk and addressing the burden of *P. vivax*.

INTRODUCTION

Global support for malaria eradication has fluctuated in response to changing health policies

over the past 75 years. From near global endemicity in the 1900's [1] over 100 countries have

eliminated malaria,[2] with 10 of these certified malaria-free by the World Health Organization

(WHO) in the last two decades.[3] Despite this success, 41% and 57% of the global population

in 2017 were estimated to live in areas at risk of infection with *Plasmodium falciparum* and

Plasmodium vivax, respectively.[3,4] In 2020 there were an estimated 241 million new malaria

cases and over 600,000 deaths, primarily in children under 5 years of age.[5] Mosquito

resistance to the insecticides used in vector control, parasite resistance to both first-line

therapeutics and diagnostics, and local active conflicts continue to threaten elimination

efforts.[6] Nevertheless, the global community continues to strive towards the ultimate aim of

eradication, which could ultimately save millions of lives and thus offer high returns on

investment.[7,8]

The global goals outlined in the Global Technical Strategy for Malaria (GTS) 2016-2030 [9]

include reducing malaria incidence and mortality rates by 90%, achieving elimination in 35

countries, and preventing re-establishment of transmission in all countries currently classified as

malaria-free by 2030. Various stakeholders have also set timelines for the wider goal of global

eradication, ranging from 2030 to 2050.[6–8] However, there remains a lack of consensus on

how best to achieve this longer-term aspiration. Whilst it is widely acknowledged that the current

tool set is insufficient in itself to eradicate the parasite, there continues to be debate about how

resources should be allocated. Some advocate for a focus on high-burden settings to lower the

overall global burden,[10] while others call for increased funding to middle-income low-burden

countries through a 'shrink the map strategy' where elimination is considered a driver of global

progress.[11] A third set of policy options is influenced by equity considerations including

allocating funds to achieve equal allocation per person at risk, equal access to bed nets and

treatment, maximize lives saved, or to achieve equitable overall health status.[12,13]

Global strategies are influenced by international donors, which represent 68% of the global

investment in malaria control and elimination activities.[5] The Global Fund and the U.S.

President's Malaria Initiative are two of the largest contributors to this investment. Their

strategies pursue a combination approach, prioritizing malaria reduction in high-burden

countries while achieving sub-regional elimination in select settings.[14,15] Given that the global

investment for malaria control and elimination still falls short of the 6.8 billion USD currently

estimated to be needed to meet GTS 2016-2030 goals,[6] an optimized strategy to allocate

limited resources is critical to maximizing the chance of successfully achieving the GTS goals

and longer-term eradication aspirations.

In this study, we use mathematical modelling to explore the optimal allocation of limited global

resources to maximize the long-term reduction in *P. falciparum* and *P. vivax* malaria. Our aim is

to determine whether financial resources should initially focus on high-transmission countries,

low-transmission countries, or a balance between the two across a range of global budgets. In

doing so, we consider potential trade-offs between short-term gains and long-term impact. We

use compartmental deterministic versions of two previously developed and tested individual-

based model of *P. falciparum* and *P. vivax* transmission respectively.[16,17] Using the

compartmental model structures allows us to fully explore the space of possible resource

allocation decision using optimization, which would be prohibitively costly to perform using more

complex individual-based models. Furthermore, to evaluate the impact of resource allocation

options, we focus on a single intervention - insecticide-treated nets (ITNs). Whilst in reality

national malaria elimination programs encompass a broad range of preventative and therapeutic

tools alongside different surveillance strategies as transmission decreases, this simplification is

made for computational feasibility, with ITNs chosen as they (a) provide both an individual

protective effects and population-level transmission reductions (i.e. indirect effects); (b) are the

most widely used single malaria intervention other than first-line treatment; and (c) extensive

distribution and costing data are available that allow us to incorporate their decreasing technical

efficiency at high coverage.

RESULTS

We identified 105 malaria-endemic countries based on 2000 *P. falciparum* and *P. vivax*

prevalence estimates (before the scale-up of interventions), of which 44, 9, and 52 were

endemic for *P. falciparum* only, *P. vivax* only, and co-endemic for both species, respectively.

Globally, the clinical burden of malaria was focused in settings of high transmission intensity

endemic for *P. falciparum* only, followed by low-transmission settings co-endemic for *P.*

falciparum and *P. vivax* (**Figure 1A**). Conversely, 89% of the global population at risk of malaria

was located in co-endemic settings with very low and low transmission intensities (**Figure 1B**).

All 25 countries with high transmission intensity and 11 of 17 countries with moderate

transmission intensity were in Africa, while almost half of global cases and population at risk in

low-transmission co-endemic settings originated in India.

Deterministic compartmental versions of two previously published and validated mathematical

models of *P. falciparum* and *P. vivax* malaria transmission dynamics [16,18–20] were used to

explore associations between ITN use and clinical malaria incidence. In model simulations, the

relationship between ITN usage and malaria infection outcomes varied by the baseline

entomological inoculation rate (EIR), representing local transmission intensity, and parasite

species (**Figure 2**). The same increase in ITN usage achieved a larger relative reduction in

clinical incidence in low-EIR than in high-EIR settings. Low levels of ITN usage were sufficient to

eliminate malaria in low-transmission settings, whereas high ITN usage was necessary to

achieve a substantial decrease in clinical incidence in high-EIR settings. At the same EIR value,

ITNs also led to a larger relative reduction in *P. falciparum* than *P. vivax* clinical incidence.

However, ITN usage of 80% was not sufficient to lead to full elimination of either *P. falciparum*

or *P. vivax* in the highest transmission settings. In combination, the models projected that ITNs

could reduce global *P. falciparum* and *P. vivax* cases by 83.6% from 252.0 million and by 99.9%

from 69.3 million, respectively, assuming a maximum ITN usage of 80%.

We next used a non-linear generalized simulated annealing function to determine the optimal

global resource allocation for ITNs across a range of budgets. We defined optimality as the

funding allocation across countries which minimizes a given objective. We considered two

objectives: first, reducing the global number of clinical malaria cases, and second, reducing both

the global number of clinical cases and the number of settings not having yet reached a pre-

elimination phase. The latter can be interpreted as accounting for an additional positive

contribution of progressing towards elimination on top of a reduced case burden (e.g. general

health system strengthening through a reduced focus on malaria). To relate funding to impact

on malaria, we incorporated a non-linear relationship between costs and ITN usage, resulting in

an increase in the marginal cost of ITN distribution at high coverage levels.[21] We considered a

range of fixed budgets, with the maximum budget being that which enabled achieving the lowest

possible number of cases in the model. Low, intermediate and high budget levels refer to 25%,

50% and 75% of this maximum, respectively.

In our main analysis we ignored the time dimension over which funds are distributed, instead

focusing on the endemic equilibrium reached for each level of allocation (sensitivity to this

assumption is explored in supplementary results with dynamic re-allocation every 3 years). The

optimal strategies were compared with three existing approaches to resource allocation: 1)

prioritization of high-transmission settings, 2) prioritization of low-transmission (near-elimination)

settings, and 3) proportional allocation by disease burden.

We found that the optimal strategies for reducing total malaria cases (i.e. global burden) and for

case reduction and pre-elimination to be similar to the strategy that prioritized funding for high-

transmission settings. These three strategies achieved the largest reductions in global malaria

cases at all budgets, including reductions of 76%, 73% and 66% at the intermediate budget

level, respectively (**Figure 3A**, **Table 1**). At low to intermediate budgets, the proportional

allocation strategy also reduced malaria cases effectively by up to 53%. While these four

scenarios had very similar effects on malaria cases at low budgets, they diverged with

increasing funding, where the proportional allocation strategy did not achieve substantial further

reductions. Depending on the available budget, the optimal strategy for case reduction averted

up to 31% more cases than prioritization of high-transmission settings and 64% more cases

than proportional allocation, corresponding to respective differences of 37.9 and 74.5 million

cases globally.

We additionally found there to be a trade-off between reducing global cases and reducing the

global population at risk of malaria. Both the optimal strategies and the strategy prioritizing high-

transmission settings did not achieve substantial reductions in the global population at risk until

large investments were reached (**Figure 3B, Table 1**). Even at a high budget, the global

population at risk was only reduced by 19% under the scenario prioritizing high-transmission

settings, with higher reductions of 42-58% for the optimal strategies, while   proportional

allocation had almost no effect on this outcome. Conversely, diverting funding to prioritize low-

transmission settings was highly effective at increasing the number of settings eliminating

malaria, achieving a 56% reduction in the global population at risk already at intermediate

budgets. However, this investment only led to a minimal reduction of 24% in total malaria case

load (**Figure 3**, **Table 1**). At high budget levels, prioritizing low-transmission settings resulted in

up to 3.8 times (a total of 159.4 million) more cases than the optimal allocation for case

reduction. Despite the population at risk remaining relatively large with the optimal strategy for

case reduction and pre-elimination, it nevertheless led to pre-elimination in more malaria-

endemic settings than all other strategies (Figure S7), in addition to close to minimum cases

across all budgets (**Figure 3**).

The allocation strategies also had differential impacts on *P. falciparum* and *P. vivax* cases, with

case reductions generally occurring first for *P. falciparum* except when prioritizing low-

transmission settings. *P. vivax* cases were not substantially affected at low global budgets for all

other allocation strategies, and proportional allocation had almost no effect on reducing *P. vivax*

clinical burden at any budget (**Figure 3C**), leading to a temporary increase in the proportion of

total cases attributable to *P. vivax* relative to *P. falciparum*. The global population at risk

remained high with the optimal strategy for case reduction even at high budgets, partly due to a

large remaining population at risk of *P. vivax* infection (**Figure 3D**), which was not targeted

when aiming to minimize total cases (**Figure 1**).

The optimized distribution of funding to minimize clinical burden depended on the available

global budget and was driven by the setting-specific transmission intensity and the population at

risk (**Figure 4**, **Figure 1**). With very low to low budget levels, as much as 85% of funding was

allocated to moderate to high transmission settings (**Figure 4A, Figure S8A**). This allocation

pattern led to the maximum ITN usage of 80% being reached in settings of high transmission

intensity and smaller population sizes even at low budgets, while maintaining lower levels in

low-transmission settings with larger populations (**Figure 4B, Figure S8B**). The proportion of

the budget allocated to low and very low transmission settings increased with increasing

budgets, and low transmission settings received the majority of funding at intermediate to

maximum budgets. This allocation pattern remained very similar when optimizing for both case

reduction and pre-elimination (**Figure S9).** Similar patterns were also observed for the optimized

distribution of funding between settings endemic for only *P. falciparum* compared to *P.*

falciparum and *P. vivax* co-endemic settings (**Figure 4C-D**), with the former being prioritized at

low to intermediate budgets. At the maximum budget, 70% of global funding was targeted at

low- and very low-transmission settings co-endemic for both parasite species.

Results remained similar when relaxing assumptions about ITN distribution efficiency (**Figure**

S10). Furthermore, at high budgets, capturing dynamic changes over time through re-allocation

of funding based on minimizing *P. falciparum* cases every 3 years led to the same case

reductions over time as a one-time optimization with allocation of a constant ITN usage (**Figure**

S11). At lower budgets, re-allocation every 3 years achieved a higher impact at several

timepoints, but total cases remained similar between the two approaches. Although reallocation

of resources from settings which achieved elimination to higher transmission settings did not

lead to substantially fewer cases, it reduced total spending over the 39-year period in some

cases (**Figure S11**).

DISCUSSION

Our study highlights the potential impact that funding allocation decisions could have on the

global burden of malaria. We estimated that optimizing ITN allocation to minimize global clinical

incidence could avert 83% of clinical cases compared to no intervention with a high budget. In

comparison, the optimal strategy to minimize clinical incidence and maximize the number of

settings reaching pre-elimination averted 82% of clinical cases, prioritizing high-transmission

settings 81%, proportional allocation 61%, and prioritizing low-transmission settings 37%. Our

results support initially prioritizing funding towards reaching high ITN usage in the high-burden

P. falciparum-endemic settings to minimize global clinical cases and advance elimination in

more malaria-endemic settings, but highlight the trade-off between this strategy and reducing

the global population at risk of malaria as well as addressing the burden of *P. vivax*.

Prioritizing low-transmission settings demonstrated how focusing on "shrinking the malaria map"

by quickly reaching elimination in low-transmission countries diverts funding away from the high-

burden countries with the largest caseloads. Prioritizing low-transmission settings achieved

elimination in 42% of settings and reduced the global population at risk by 56% when 50% of

the maximum budget had been spent, but also resulted in 3.2 times more clinical cases than the

optimal allocation scenario. Investing a larger share of global funding towards high-transmission

settings aligns more closely with the current WHO "high burden to high impact" approach, which

places an emphasis on reducing the malaria burden in the 11 countries which comprise 70% of

global cases.[22] Previous research supports this approach, finding that the 20 highest burden

countries would need to obtain 88% of global investments to reach case and mortality risk

estimates in alignment with GTS goals.[23] This is similar to the modelled optimized funding

strategy presented here, which allocated up to 76% of very low budgets to settings of high

transmission intensity located in sub-Saharan Africa. An initial focus on high- and moderate-

transmission settings is further supported by our results showing that a balance can be found

between achieving close to optimal case reductions while also progressing towards elimination

in the maximum number of settings. Even within a single country, targeting interventions to local

hot-spots has been shown to lead to higher cost savings than universal application,[28] and

could lead to elimination in settings where untargeted interventions would have little impact.[25]

Assessing optimal funding patterns is a global priority due to the funding gap between supply

and demand for resources for malaria control and elimination.[5] However, allocation decisions

will remain important even if more funding became available, as some of the largest differences

in total cases between the modelled strategies occurred at intermediate to high budgets. Our

results suggest that most of global funding should only be focused in low-transmission settings

co-endemic for *P. falciparum* and *P. vivax* at high budgets once ITN use has already been

maximized in high-transmission settings. Global allocation decisions are likely to affect *P.*

falciparum and *P. vivax* burden differently, which could have implications for the future global

epidemiology of malaria. For example, with a focus on disease burden reduction, a temporary

increase in the proportion of malaria cases attributable to *P. vivax* was projected, in line with

recent observations in near-elimination areas.[4,26] Nevertheless, even when international

funding for malaria increased between 2007-2009, African countries remained the major

recipients of financial support, while *P. vivax*-dominant countries were not as well funded.[27]

This serves as a reminder that achieving elimination of malaria from all endemic countries will

ultimately require targeting investments so as to also address the burden of *P. vivax* malaria.

Different priorities in resource allocation decisions greatly affect which countries receive funding

and what health benefits are achieved. The modelled strategies follow key ethical principles in

the allocation of scarce healthcare resources, such as targeting those of greatest need

(*prioritizing high-transmission settings, proportional allocation*) or those with the largest

expected health gain (*optimized for case reduction, prioritizing high-transmission settings*).[12]

Allocation proportional to disease burden did not achieve as great an impact as other strategies

because the funding share assigned to settings was constant irrespective of the invested budget

and its impact, and we did not reassign excess funding in high-transmission settings to other

malaria interventions. This illustrates the possibility that such an allocation approach can

potentially target certain countries disproportionally and result in further inequities in health

outcomes.[28] From an international funder perspective, achieving vertical equity might

therefore also encompass higher disbursements to countries with lower affordability of malaria

interventions,[28] as reflected in the Global Fund's proportional allocation formula which

accounts for the economic capacity of countries.[14]

While our models are based on country patterns of transmission settings and corresponding

populations in 2000, there are several factors leading to heterogeneity in transmission dynamics

at the national and sub-national level which were not modelled and limit our conclusions.

Seasonality, changing population size, and geographic variation in *P. vivax* relapse patterns or

in mosquito vectors could affect the projected impact of ITNs and optimized distribution of

resources across settings. The two representative *Anopheles* species used in the simulations

are also both very anthropophagic, which may have led to overestimation of the effect of ITNs in

some settings. By using ITNs as the sole means to reduce mosquito-to-human transmission, we

did not capture the complexities of other key interventions that play a role in burden reduction

and elimination, the geospatial heterogeneity in cost-effectiveness and optimized distribution of

intervention packages on a sub-national level, or related pricing dynamics.[29,30] For *P. vivax* in

particular, reducing the global economic burden and achieving elimination will depend on

incorporation of hypnozoitocidal treatment and G6PD screening into case management.[31]

Furthermore, for both parasites, intervention strategies generally become more focal as

transmission decreases, with targeted surveillance and response strategies prioritized over

widespread vector control. Therefore, policy decisions should additionally be based on analysis

of country-specific contexts. Results do however account for non-linearities in the relationship

between ITN distribution and usage to represent changes in cost as a country moves from

control to elimination: interventions that are effective in malaria control settings, such as

widespread vector control, may be phased out or limited in favor of more expensive active

surveillance and a focus on confirmed diagnoses and at-risk populations.[2] We also assumed

that transmission settings are independent of each other, and did not allow for the possibility of

re-introduction of disease, such as has occurred throughout the Eastern Mediterranean from

imported cases.[32] In practice, this threat of malaria resurgence has important implications for

considerations of when to scale back interventions.

Our analysis demonstrates the most impactful allocation of a global funding portfolio for malaria

to reduce global cases. Unifying all funding sources in a global strategic allocation framework as

presented here requires international donor allocation decisions to account for available

domestic resources. National governments of endemic countries contribute 31% of all malaria-

directed funding globally,[6] and government financing is a major source of malaria spending in

near-elimination countries in particular.[33] Within the wider political economy which shapes the

funding landscape and priority setting, there remains substantial scope for optimizing allocation

decisions, including improving efficiency of within-country allocation of malaria interventions.

Subnational malaria elimination in localized settings within a country can also provide motivation

for continued elimination in other areas and friendly competition between regions to boost global

elimination efforts.[34] Although more efficient allocation cannot fully compensate for projected

shortfalls in malaria funding, mathematical modelling can aid efforts in determining optimal

approaches to achieve the largest possible impact with available resources.

MATERIALS AND METHODS

Transmission models

We used deterministic compartmental versions of two previously published individual-based

transmission models of *P. falciparum* and *P. vivax* malaria to estimate the impact of varying ITN

usage on clinical incidence in different transmission settings. The *P. falciparum* model has

previously been fitted to age-stratified data from a variety of sub-Saharan African settings to

recreate observed patterns in parasite prevalence ($PfPR_{2-10}$), the incidence of clinical disease,

immunity profiles, and vector components relating rainfall, mosquito density, and the

entomological inoculation rate (EIR).[18] We developed a deterministic version of an existing

individual-based model of *P. vivax* transmission, originally calibrated to data from Papua New

Guinea but also shown to reproduce global patterns of *P. vivax* prevalence and clinical

incidence.[17] Models for both parasite species are structured by age and heterogeneity in

exposure to mosquito bites, and account for human immunity patterns. They model mosquito

transmission and population dynamics, and the impact of scale-up of ITNs in identical ways. Full

assumptions, mathematical details and parameter values can be found in the Supplementary

Material and in previous publications.[16,18]

Data sources

We calibrated the model to baseline transmission intensity in all malaria-endemic countries

before scale-up of interventions, using the year 2000 as an indicator of these levels. Annual EIR

was used as a measure of parasite transmission intensity, representing the rate at which people

are bitten by infectious mosquitoes. We simulated models to represent a wide range of EIRs for

P. falciparum and *P. vivax*. These transmission settings were matched to 2000 country-level

prevalence data [3,4] resulting in EIRs of 0.001-80 for *P. falciparum* and 0.001-1.3 for *P. vivax.*

P. falciparum estimates came from parasite prevalence in children aged 2-10 years and *P. vivax*

prevalence estimates came from light microscopy data across all ages, based on standard

reporting for each species. The relationship between parasite prevalence and EIR for specific

countries is shown in **Figures S5 and S6**. In each country, the population at risk for *P.*

falciparum and *P. vivax* malaria was obtained by summing WorldPop gridded 2000 global

population estimates[35] within Malaria Atlas Project transmission spatial limits using

geoboundaries [36] (Supplementary Materials: Country-level data). As this exercise represents

a simplification of reality, population sizes were held constant, and projected population growth

is not reflected in the number of cases and the population at risk in different settings.

Seasonality was also not incorporated in the model, as EIRs are matched to annual prevalence

estimates and the effects of seasonal changes are averaged across the time frame captured.

For all analyses, countries were grouped according to their EIR, resulting in a range of

transmission settings compatible with the global distribution of malaria. Results were further

summarized by grouping EIRs into broader transmission intensity settings according to WHO

prevalence cut-offs.[37] EIRs of less than 0.1, 0.1 to 1, 1 to 7 and 7 or higher were defined as

very low, low, moderate and high transmission intensity, respectively.

Interventions

In all transmission settings, we simulated the impact of varying coverages of ITNs on clinical

incidence. While most countries implement a package of combined interventions, to reduce the

computational complexity of the optimization we considered the impact of ITN usage alone in

addition to 40% treatment of clinical disease. ITNs are a core intervention recommended for

large-scale deployment in areas with ongoing malaria transmission by WHO[38,39]and funding

for vector control represents much of global investments required for malaria control and

elimination.[23] Modelled coverages represent population ITN usage between 0 and 80%, with

the upper limit reflective of common targets for universal access.[40] In each setting, the models

were run until clinical incidence stabilized at a new equilibrium with the given ITN usage.

Previous studies have shown that, as population coverage of ITNs increases, the marginal cost

of distribution increases as well.[21] We incorporated this non-linearity in costs by estimating the

annual ITN distribution required to achieve the simulated population usage based on published

data from across Africa, assuming that nets would be distributed on a 3-yearly cycle and

accounting for ITN retention over time (Supplementary Material). The cost associated with a

given simulated ITN usage was calculated by multiplying the number of nets distributed per

capita per year by the population size and by the unit cost of distributing an ITN, assumed to be

$3.50.[41]

Optimization

The optimal funding allocation for case reduction was determined by finding the allocation of ITNs b across transmission settings that minimizes the total number of malaria cases at equilibrium. Case totals were calculated as the sum of the product of clinical incidence $cinc_i$ and the population p_i in each transmission setting i. Resource allocation must respect a budget constraint, which requires that the sum of the cost of the ITNs distributed cannot exceed the initial budget B, with b_i the initial number of ITNs distributed in setting i and c the cost of a single pyrethroid-treated net. The second constraint requires that the ITN usage $b_i^\star$ must be between 0 and 80% [40], with ITN usage being a function of ITNs distributed, as shown in the following equation.

$$\min_{b \in \mathbb{R}^n} \sum_{i=1}^{n} cinc_i * p_i$$

$$\text{s.t.} \quad \sum_{i=1}^{n} b_i * c \leq B$$

$$0 \leq b_i^\star \leq 0.8 \quad \forall i = 1, \dots, n$$

$$\text{with} \quad b_i^\star = f(b_i)$$

Simultaneous optimization for case reduction and pre-elimination was implemented with an extra weighting term in the objective function, corresponding to a positive contribution for each setting reaching the pre-elimination phase. The weighting on pre-elimination compared to case reduction was varied between 0.5 and 100 times the total cases averted by the ITN allocation. The optimization was undertaken using generalized simulated annealing.[42] We included a penalty term in the objective function to incorporate linear constraints. Further details can be found in the Supplementary Material.

The optimal allocation strategy for minimizing cases was also examined over a period of 39

years using the *P. falciparum* model, comparing a single allocation of a constant ITN usage to

minimize clinical incidence at 39 years, to reallocation every 3 years (similar to Global Fund

allocation periods [43]) leading to varying ITN usage over time. At the beginning of each 3-year

period, we determined the optimized allocation of resources to be held fixed until the next round

of funding, with the objective of minimizing 3-year global clinical incidence. Once *P. falciparum*

elimination is reached in a given setting, ITN distribution is discontinued, and in the next period

the same total budget B will be distributed among the remaining settings. We calculated the

total budget required to minimize case numbers at 39 years and compared the impact of re-

allocating each 3 years with a one-time allocation of 25%, 50%, 75% and 100% of the budget.

Analysis

We compared the impact of the two optimal allocation strategies (scenario 1A and 1B) and three

additional allocation scenarios on global malaria cases and the global population at risk.

Modelled scenarios are shown in **Table 2**. Scenarios 1C-1E represent existing policy strategies

that involve prioritizing high-transmission settings, prioritizing low-transmission (near-

elimination) settings, or resource allocation proportional to disease burden in the year 2000.

Certification of malaria elimination requires proof that the chain of indigenous malaria

transmission has been interrupted for at least 3 years and a demonstrated capacity to prevent

return transmission.[44] In our analysis, transmission settings were defined as having reached

malaria elimination once less than one case remained per the setting's total population. Once a

setting reaches elimination, the entire population is removed from the global total population at

risk, representing a 'shrink the map' strategy. The pre-elimination phase was defined as having

reached less than 1 case per 1000 persons at risk in a setting.

All strategies were evaluated at different budgets ranging from 0 to the minimum investment

required to achieve the lowest possible number of cases in the model (noting that ITNs alone

are not predicted to eradicate malaria in our model). No distinctions were made between

national government spending and international donor funding, as the purpose of the analysis

was to look at resource allocation and not to recommend specific internal and external funding

choices.

All analyses were conducted in R v. 4.0.5 (R Foundation for Statistical Computing, Vienna,

Austria). The sf (v. 0.9-8, Pebesma 2018), raster (v. 3.4-10, Hijmans & van Etten 2012), and

terra (v.1.3-4, Hijmans 2021) packages were used for spatial data manipulation. The akima

package (v.0.6-2.2, Akima and Gebhardt 2021) was used for surface development, and the

GenSA package (v.1.1.7, Gubian et al.) for model optimization.

REFERENCES

1. Feachem RGA, Phillips AA, Hwang J, Cotter C, Wielgosz B, Greenwood BM, et al. Shrinking the malaria map: progress and prospects. Lancet. 2010/10/28. 2010;376: 1566–1578. doi:10.1016/S0140-6736(10)61270-6

2. Shretta R, Liu J, Cotter C, Al. E. Malaria Elimination and Eradication. 3rd ed. In: Holmes K, Bertozzi S, Bloom B, Al. E, editors. Major Infectious Diseases. 3rd ed. Washington, DC: The International Bank for Reconstruction and Development / The World Bank; 2017.

3. Weiss DJ, Lucas TCD, Nguyen M, Nandi AK, Bisanzio D, Battle KE, et al. Mapping the global prevalence, incidence, and mortality of Plasmodium falciparum, 2000–17: a spatial and temporal modelling study. The Lancet. 2019;394: 322–331. doi:10.1016/S0140-6736(19)31097-9

4. Battle KE, Lucas TCD, Nguyen M, Howes RE, Nandi AK, Twohig KA, et al. Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000–17: a spatial and temporal modelling study. The Lancet. 2019;394: 332–343. doi:10.1016/S0140-6736(19)31096-7

5. World malaria report 2021. Geneva; 2021. Available: https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2021

6. World malaria report 2020: 20 years of global progress and challenges. Geneva; 2020.

7. Chen I, Cooney R, Feachem RGA, Lal A, Mpanju-Shumbusho W. The Lancet Commission on malaria eradication. Lancet. 2018;391: 1556–1558. doi:10.1016/S0140-6736(18)30911-5

8. Strategic Advisory Group on Malaria Eradication. Malaria eradication: benefits, future scenarios & feasibility. A report of the Strategic Advisory Group on Malaria Eradication. Geneva; 2020.

9. Global Technical Strategy for Malaria 2016-2030. Geneva; 2015. Available: http://apps.who.int/iris/bitstream/10665/176712/1/9789241564991_eng.pdf?ua=1&ua=1

10. WHO/CDS/GMP. High burden to high impact: a targeted malaria response. Geneva; 2019.

11. Newby G, Bennett A, Larson E, Cotter C, Shretta R, Phillips AA, et al. The path to eradication: a progress report on the malaria-eliminating countries. Lancet. 2016;387: 1775–1784. doi:10.1016/S0140-6736(16)00230-0

12. Briefing note - How should funds for malaria control be spent when there are not enough? Geneva; 2013. Available: https://www.who.int/malaria/mpac/resource_allocation_mpac_brief.pdf

13. Raine R, Or Z, Prady S, Bevan G. Evaluating health-care equity. 2016 [cited 3 May 2022]. doi:10.3310/HSDR04160-69

14. Approval of the Global Fund Strategy Narrative. 46th Board Meeting. GF/B46/03 Revision 1. . Geneva; 2021.

478   15.   USAID, CDC. End Malaria Faster. U.S. President's Malaria Initiative Strategy
479   2021-2026. Washington, DC; 2021.

480   16.   Griffin JT, Hollingsworth TD, Okell LC, Churcher TS, White M, Hinsley W, et al.
481   Reducing Plasmodium falciparum malaria transmission in Africa: a model-
482   based evaluation of intervention strategies. PLoS Med. 2010;7: e1000324.
483   doi:10.1371/journal.pmed.1000324

484   17.   White MT, Walker P, Karl S, Hetzel MW, Freeman T, Waltmann A, et al.
485   Mathematical modelling of the impact of expanding levels of malaria control
486   interventions on Plasmodium vivax. Nature Communications 2018 9:1. 2018;9: 1–
487   10. doi:10.1038/s41467-018-05860-8

488   18.   Griffin JT, Ferguson NM, Ghani AC. Estimates of the changing age-burden of
489   Plasmodium falciparum malaria disease in sub-Saharan Africa. Nat Commun.
490   2014;5: 3136. doi:10.1038/ncomms4136

491   19.   White MT, Griffin JT, Churcher TS, Ferguson NM, Basáñez M-G, Ghani AC.
492   Modelling the impact of vector control interventions on Anopheles gambiae
493   population dynamics. Parasit Vectors. 2011;4: 153. doi:10.1186/1756-3305-4-153

494   20.   Griffin JT, Bhatt S, Sinka ME, Gething PW, Lynch M, Patouillard E, et al. Potential
495   for reduction of burden and local elimination of malaria by reducing Plasmodium
496   falciparum malaria transmission: a mathematical modelling study. Lancet Infect
497   Dis. 2016;16: 465–472. doi:10.1016/S1473-3099(15)00423-5

498   21.   Bertozzi-Villa A, Bever CA, Koenker H, Weiss DJ, Vargas-Ruiz C, Nandi AK, et al.
499   Maps and metrics of insecticide-treated net access, use, and nets-per-capita
500   in Africa from 2000-2020. Nat Commun. 2021;12: 3589. doi:10.1038/s41467-021-
501   23707-7

502   22.   WHO/CDS/GMP/. High burden to high impact: a targeted malaria response. 2019.
503   Available: https://www.who.int/publications/i/item/WHO-CDS-GMP-2018.25

504   23.   Patouillard E, Griffin J, Bhatt S, Ghani A, Cibulskis R. Global investment targets for
505   malaria control and elimination between 2016 and 2030. BMJ Glob Health. 2017;2.
506   doi:10.1136/bmjgh-2016-000176

507   24.   Walker PGT, Griffin JT, Ferguson NM, Ghani AC. Estimating the most efficient
508   allocation of interventions to achieve reductions in Plasmodium falciparum malaria
509   burden and transmission in Africa: a modelling study. Lancet Glob Health. 2016;4:
510   e474-84. doi:10.1016/S2214-109X(16)30073-0

511   25.   Bousema T, Griffin JT, Sauerwein RW, Smith DL, Churcher TS, Takken W, et al.
512   Hitting Hotspots: Spatial Targeting of Malaria for Control and Elimination. PLoS
513   Med. 2012;9: e1001165. doi:10.1371/JOURNAL.PMED.1001165

514   26.   Price RN, Commons RJ, Battle KE, Thriemer K, Mendis K. Plasmodium vivax in
515   the Era of the Shrinking P. falciparum Map. Trends Parasitol. 2020;36: 560–570.
516   doi:10.1016/J.PT.2020.03.009

517   27.   Snow RW, Okiro EA, Gething PW, Atun R, Hay SI. Equity and adequacy of
518   international donor assistance for global malaria control: an analysis of populations
519   at risk and external funding commitments. The Lancet. 2010;376: 1409–1416.
520   doi:10.1016/S0140-6736(10)61340-2

28. Barrenho E, Miraldo M, Shaikh M, Atun R. Vertical and horizontal equity of funding
for malaria control: a global multisource funding analysis for 2006–2010. BMJ Glob
Health. 2017;2. doi:10.1136/BMJGH-2017-000496
29. Conteh L, Shuford K, Agboraw E, Kont M, Kolaczinski J, Patouillard E. Costs and
Cost-Effectiveness of Malaria Control Interventions: A Systematic Literature
Review. Value in Health. 2021. doi:10.1016/J.JVAL.2021.01.013
30. Drake TL, Lubell Y, Kyaw SS, Devine A, Kyaw MP, Day NPJ, et al. Geographic
Resource Allocation Based on Cost Effectiveness: An Application to Malaria
Policy. Appl Health Econ Health Policy. 2017;15: 299–306. doi:10.1007/S40258-
017-0305-2/FIGURES/3
31. Devine A, Battle KE, Meagher N, Howes RE, Dini S, Gething PW, et al. Global
economic costs due to vivax malaria and the potential impact of its radical cure: A
modelling study. PLoS Med. 2021;18: e1003614.
doi:10.1371/JOURNAL.PMED.1003614
32. WHO Regional Office for the Eastern Mediterranean. Guidelines on prevention of
the reintroduction of malaria. EMRO Technical Publications Series 34. Cairo; 2007.
33. Haakenstad A, Harle AC, Tsakalos G, Micah AE, Tao T, Anjomshoa M, et al.
Articles Tracking spending on malaria by source in 106 countries, 2000-16: an
economic modelling study. Lancet Infect Dis. 2019;19: 703–716.
doi:10.1016/S1473-3099(19)30165-3
34. Lindblade KA, Kachur SP. Opportunities for Subnational Malaria Elimination in
High-Burden Countries. Am J Trop Med Hyg. 2020;103: 2153.
doi:10.4269/AJTMH.20-1342
35. Tatem AJ. WorldPop, open data for spatial demography. Scientific Data. Nature
Publishing Groups; 2017. pp. 1–4. doi:10.1038/sdata.2017.4
36. Runfola D, Anderson A, Baier H, Crittenden M, Dowker E, Fuhrig S, et al.
geoBoundaries: A global database of political administrative boundaries. PLoS
One. 2020;15: e0231866. doi:10.1371/JOURNAL.PONE.0231866
37. WHO Guidelines for malaria. Geneva; 2022. Available:
https://www.who.int/publications/i/item/guidelines-for-malaria
38. Winskill P, Walker PG, Cibulskis RE, Ghani AC. Prioritizing the scale-up of
interventions for malaria control and elimination. Malar J. 2019;18: 1–11.
doi:10.1186/S12936-019-2755-5/FIGURES/5
39. WHO Guidelines for malaria. [cited 24 Oct 2022]. Available:
https://www.who.int/publications/i/item/guidelines-for-malaria
40. Koenker H, Arnold F, Ba F, Cisse M, Diouf L, Eckert E, et al. Assessing whether
universal coverage with insecticide-treated nets has been achieved: is the right
indicator being used? Malar J. 2018;17. doi:10.1186/S12936-018-2505-0
41. Sherrard-Smith E, Winskill P, Hamlet A, Ngufor C, N'Guessan R, Guelbeogo MW,
et al. Optimising the deployment of vector control tools against malaria: a data-
informed modelling study. Lancet Planet Health. 2022;6: e100–e109.
doi:10.1016/S2542-5196(21)00296-5
42. Xiang Y, Gubian S, Suomela B, Hoeng J. Generalized simulated annealing for
global optimization: the GenSA package. R J. 2013;5: 13–28.

43.   The Global Fund. The Global Fund Strategy 2017-2022: Investing to end
566   epidemics. Geneva; 2016.
567   44.   Update on the e-2020 initiative of 21 malaria-eliminating countries: report and
568   country briefs. Geneva; 2018.
569
570

 FIGURES AND TABLES

Figure 1. Global distribution of *P. falciparum* and *P. vivax* malaria burden in 2000 (in the absence of insecticide-treated nets) obtained from the Malaria Atlas Project.[3] A) The annual number of clinical cases and B) the population at risk of malaria across settings with different transmission intensities and endemic for *P. falciparum*, *P. vivax* or co-endemic for both species. The number of countries in each setting is indicated below the figure.

578
579 **Figure 2.** Modelled impact of insecticide-treated net (ITN) usage on malaria epidemiology by

580 the setting-specific transmission intensity, represented by the baseline entomological inoculation

581 rate. The impact on the clinical incidence and prevalence of *P. falciparum* malaria (panels A and

582 B) and on the clinical incidence and prevalence of *P. vivax* malaria (panels C and D) is shown.

583 Panels A and C represent the clinical incidence for all ages.

Figure 3. Global clinical cases and population at risk of malaria under different allocation strategies at varying budgets. The impact on total malaria cases (panel A), total population at risk (panel B), individual *P. falciparum* and *P. vivax* cases (panel C) and population at risk of either species (panel D) are shown. Budget levels range from 0, representing no usage of insecticide-treated nets, to the budget required to achieve the maximum possible impact. Optimizing for case reduction generally leads to declining populations at risk as the budget increases, but this is not guaranteed due to the possibility of redistribution of funding between settings to minimize cases. The strategy optimizing case reduction and pre-elimination shown here places the same weighting (1:1) on reaching pre-elimination in a setting as on averting total cases, but conclusions were the same for weights of 0.5-100 on pre-elimination.

Figure 4. Optimal strategy for funding allocation across settings to minimize malaria case

burden at varying budgets. Panels show optimized allocation patterns across settings of

different transmission intensity (panels A and B) and different endemic parasite species (panels

C and D). The proportion of the total budget allocated to each setting (panels A and C) and the

resulting mean population usage of insecticide-treated nets (ITNs) (panels B and D) are shown.

Table 1. Relative reduction in malaria cases and population at risk under different allocation

strategies. Reductions are shown relative to the baseline of 321 million clinical cases and 4.1

billion persons at risk in the absence of interventions. Low, intermediate and high budget levels

represent 25%, 50% and 75% of the maximum budget, respectively. The strategy optimizing

case reduction and pre-elimination shown here places the same weighting (1:1) on reaching

pre-elimination in a setting as on averting total cases.

SCENARIO	Budget level	Clinical cases		Population at risk	
		Number (millions)	Relative reduction (%)	Number (billions)	Relative reduction (%)
OPTIMIZED FOR CASE REDUCTION	Low	136.1	58	4.1	0
	Intermediate	77.0	76	3.9	6
	High	53.9	83	2.4	42
	Maximum	41.5	87	0.4	91
OPTIMIZED FOR CASE REDUCTION & PRE-ELIMINATION	Low	161.3	50	4.0	3
	Intermediate	87.8	73	3.5	16
	High	58.8	82	1.8	58
	Maximum	41.5	87	0.4	91
PRIORITIZE HIGH-TRANSMISSION SETTINGS	Low	153.9	52	4.0	2
	Intermediate	109.5	66	3.4	17
	High	61.8	81	3.3	19
	Maximum	41.5	87	0.4	91
PROPORTIONAL ALLOCATION	Low	166.9	48	4.1	1
	Intermediate	150.4	53	4.0	4
	High	123.8	61	4.0	4
	Maximum	116.0	64	3.9	5
PRIORITIZE LOW-TRANSMISSION SETTINGS	Low	268.2	17	2.3	44
	Intermediate	245.2	24	1.8	56
	High	202.1	37	0.5	88
	Maximum	41.5	87	0.4	91

612 **Table 2**. Overview of modelled scenarios for allocation of funding to different transmission

613 settings. Strategies 1A-1E compare resource allocation scenarios using clinical incidence

614 values from each transmission setting at equilibrium after ITN coverage has been introduced.

615 Strategies 2A-2B are compared as part of the allocation over time sub-analysis. EIR:

616 entomological inoculation rate.

	STRATEGY	MODELLING APPROACH/ASSUMPTIONS
1A	Optimized for total malaria case reduction	Generalized simulated annealing is used to determine the optimal allocation of a given budget to minimize the total number of global malaria cases.
1B	Optimized for total malaria case reduction and pre-elimination	Generalized simulated annealing is used to determine the optimal allocation of a given budget to minimize the total number of global malaria cases while placing a premium on the pre-elimination phase being reached in a setting.
1C	Prioritize high-transmission settings	Funding is allocated to groups of countries according to transmission intensity (*P. falciparum* + *P. vivax* EIR). For a given budget, the transmission settings with highest EIR are prioritized, increasing ITN coverage in increments of 1% in each setting until malaria is eliminated or until an increase in coverage leads to no further decrease in cases, before allocating to the next-highest EIR setting.
1D	Prioritize low-transmission (near-elimination) settings	Funding is allocated to groups of countries according to transmission intensity (*P. falciparum* + *P. vivax* EIR). For a given budget, the transmission settings with lowest EIR are prioritized, increasing ITN coverage in increments of 1% in each setting until malaria is eliminated or until an increase in coverage leads to no further decrease in cases, before allocating to the next-lowest EIR setting.
1E	Proportional allocation	Funding is allocated to groups of countries in proportion to their disease burden. Budget shares are calculated using country data from the World Malaria Report [6] and account for the country-specific total malaria cases (*P. falciparum* and *P. vivax*), deaths, incidence and mortality rate in 2000-2004, scaled by the subsequent increase in the population at risk.[34]
2A	One-time optimized allocation for *P. falciparum* case reduction	Generalized simulated annealing is used to determine the optimized allocation at a given budget, minimizing the total number of global *P. falciparum* cases after 39 years, resulting in constant ITN usage in each setting over this time period.
2B	Optimized allocation every	Generalized simulated annealing is used to determine

| three years for *P. falciparum* case reduction | the optimized allocation at a given budget, minimizing the total number of global *P. falciparum* cases after every 3-year period for 39 years, allowing ITN usage to vary in each setting every 3 years. |

FUNDING

This work was supported by the Wellcome Trust [reference 220900/Z/20/Z]. NS, HMT, MP,

GDC, PW, KH and ACG also acknowledge funding from the MRC Centre for Global Infectious

Disease Analysis [reference MR/R015600/1], jointly funded by the UK Medical Research

Council (MRC) and the UK Foreign, Commonwealth & Development Office (FCDO), under the

MRC/FCDO Concordat agreement and is also part of the EDCTP2 programme supported by the

European Union. KH also acknowledges funding by Community Jameel. Disclaimer: "The views

expressed are those of the author(s) and not necessarily those of the NIHR, the UK Health

Security Agency or the Department of Health and Social Care." For the purpose of open access,

the authors have applied a 'Creative Commons Attribution' (CC BY) license to any Author

Accepted Manuscript version arising from this submission.

AUTHOR CONTRIBUTIONS

N. S, H. M. T., M. P., G. D. C., K. H. and A. C. G. conceived the study. N. S., H. M. T., and M. P.

processed the data, conducted the analysis, and created the visualizations. N. S., H. M. T., M.

P. and G. D. C. developed the computational infrastructure and methodology. P. W., M. T. W.,

K. H. and A. C. G. contributed domain knowledge. K. H. and A. C. G. acquired funding for the

study and provided guidance on analysis and interpretation. N. S. and H. M. T. wrote the first

draft of the manuscript. All authors contributed to interpreting the results, reviewing and revising

the manuscript, and approved the final version for submission.

CONFLICTS OF INTEREST

No reported conflicts of interest.